Atezolizumab is a checkpoint inhibitor approved for the treatment of several types of cancers including lung cancer, kidney cancer and bladder cancer. As an immunotherapy drug, it helps activate the immune system of the body to fight cancer by blocking PD-L1 protein interaction and enabling T-cells to recognize and destroy cancer cells.
The global Atezolizumab Market is estimated to be valued at US$ 308 Million in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: The growing incidence of cancer across the world is a key factor driving the atezolizumab market. As per estimates by WHO, cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2020 worldwide. Moreover, lung cancer is the most commonly occurring cancer and is a major cause of cancer-related mortality. With rising pollution and changing lifestyle, the incidence of lung cancer is surging significantly. This rising disease prevalence provides a impetus to the demand for innovative therapies like atezolizumab, thereby propelling the market growth over the forecast period.
SWOT Analysis
Strength: Atezolizumab has emerged as a promising treatment option against NSCLC, UBC, and other cancer types. Its immunostimulatory mechanism of action enables long-term responses in some patients.
Weakness: High treatment costs associated with atezolizumab pose significant obstacles for widespread adoption. Further, primary or acquired resistance limits its effectiveness in a proportion of patients.
Opportunity: The atezolizumab market is expected to grow due to its expanding approvals in additional cancer types and treatment lines. Further opportunities lie in combination strategies to enhance clinical outcomes.
Threats: Competition from other immune checkpoint inhibitors may erode atezolizumab’s market share over time. Safety and tolerability issues could also restrict its use in some settings.
Key Takeaways
The global atezolizumab market is expected to witness high growth over the forecast period supported by an increasing patient pool and new therapeutic indications.
Regional Analysis: The Asia Pacific region currently dominates the market and is expected to maintain its leading position owing to high disease prevalence, growing healthcare expenditure, and increasing focus on cancer immunotherapy.
Key players operating in the atezolizumab market are Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc. Pfizer’s blockbuster drug, Tecentriq (atezolizumab), captured over 60% of the global market share in 2023. The company has successfully leveraged its established oncology portfolio and strong commercial infrastructure to drive sales.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
